68 Gallium–prostate-specific membrane antigen PET/computed tomography for primary and secondary staging in prostate cancer

Abstract

Key points: Preoperative staging is a generally recommended tool for risk stratification of intermediate- to high-risk prostate cancer. So far, staging of patients with prostate cancer relies mostly on morphologic imaging. Prostatespecific membrane antigen (PSMA) PET has shown to be able to contribute molecular information on distribution of the disease. Studies have shown that PSMA PET combined with conventional imaging offers similar or higher detection rates in primary staging. In patients with biochemical recurrence of prostate cancer, PSMA imaging is able to distinguish between local recurrence or lymph node metastases even at very low prostate-specific antigen levels, thus, guiding treatment decisions.